MSD had a banner year at the ESMO Asia Congress earlier this month, presenting 14 abstracts on eight different types of cancers, including gastric, esophageal, colorectal, biliary tract, kidney, urothelial, breast and gynecological cancers. Ten of these studies were focused on Asian-related data. Roche AG, meanwhile, presented Asia-specific results from the phase III Alina study in patients with ALK-positive early stage non-small-cell lung cancer.
MSD had a banner year at the ESMO Asia Congress earlier this month, presenting 14 abstracts on eight different types of cancers, including gastric, esophageal, colorectal, biliary tract, kidney, urothelial, breast and gynecological cancers. Ten of these studies were focused on Asian-related data. Roche AG, meanwhile, presented Asia-specific results from the phase III Alina study in patients with ALK-positive early stage non-small-cell lung cancer.
Researchers from Sichuan University and Chengdu Normal University have reported the discovery of novel G9a/GLP covalent inhibitors for the treatment of triple-negative breast cancer (TNBC).
Researchers from Medical University of South Carolina aimed to evaluate the potential of secreted frizzled-related protein 2 (SFRP2) as a promising novel target for breast cancer using a newly developed humanized monoclonal antibody to SFRP2 (hSFRP2 MAb) in models of this disease.
Triple-negative breast cancer (TNBC) is the most aggressive breast tumor subtype and despite treatment advances, still has shorter median overall survival rates and higher recurrence and metastatic rates than other subtypes, due to resistance to chemotherapy.
Triple-negative breast cancer (TNBC) is a highly metastatic and heterogeneous type of tumor, representing 15% of breast cancer cases. To tackle the drug-resistant phenotype of TNBC, effective targeted combinatorial approaches are urgently needed. Writing in EMBO Molecular Medicine journal, researchers from the Centre for Genomic Regulation and collaborators demonstrate that the simultaneous inhibition of lysyl oxidase-like 2 (LOXL2) and bromodomain-containing protein 4 (BRD4) synergistically limits TNBC proliferation in vitro and in vivo.
Glutaminyl-peptide cyclotransferase-like protein (QPCTL) is a modulator of CD47-SIRPα binding and can be targeted to achieve antitumor responses through myeloid checkpoint blockade. At the recent ESMO meeting in Madrid, researchers from Insilico Medicine Inc. reported the preclinical characterization of ISM-8207, a QPCTL inhibitor with activity against triple-negative breast cancer (TNBC) and diffuse large B-cell lymphoma (DLBCL).
Researchers from Birla Institute of Technology & Science, Pilani and Jadavpur University have reported novel HDAC3 inhibitors as potential candidates for the treatment of breast cancer. Synthesis and optimization of a series of pyrazino-hydrazide-based HDAC3 inhibitors led to the characterization of compound [I] as the lead candidate with potent HDAC3 inhibitory activity (IC50=14 nM) and at least 121-fold selectivity.
Previous research has shown high expression of angiotensin-converting enzyme 1 (ACE1) in the triple-negative breast cancer (TNBC) cell line MDA-MB-231, suggesting the potential of ACE1 as a novel target for this disease. In the current study, researchers from Peking University Cancer Hospital presented the discovery of [68Ga]DOTA-BPP, a novel peptide nuclide molecular imaging probe targeting ACE1 for the imaging of TNBC.
